Calcineurin inhibitors and sirolimus: Mechanisms of action and applications in dermatology

Clinical and Experimental Dermatology

Volumn 27, Issue 7, 2002, Pages 555-561

  Reynolds, N J ^a   Al Daraji, W I ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASCOMYCIN; CALCINEURIN INHIBITOR; CYCLOSPORIN; PHOSPHATASE; PIMECROLIMUS; RAPAMYCIN; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TACROLIMUS; TRANSCRIPTION FACTOR NFAT;

ATOPIC DERMATITIS; CAPILLARY LEAK SYNDROME; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; IMMUNE SYSTEM; INFLAMMATORY DISEASE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSORIASIS; REVIEW; SIDE EFFECT; SKIN DISEASE; T LYMPHOCYTE; THROMBOCYTOPENIA;

ADMINISTRATION, TOPICAL; CALCINEURIN; CYCLOSPORINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; SIROLIMUS; SKIN DISEASES; TACROLIMUS;

EID: 0036459015     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2230.2002.01148.x     Document Type: Review

References (54)

1. Stoddard BLZ, Flick KE. Calcineurin-immunosuppressor complexes. Curr Opin Struct Biol 1996; 6: 770-5.
2. Shaw AS, Dustin ML. Making the T cell receptor go the distance. A topological view of T cell activation. Immunity 1997; 6: 361-9.
3. Collins TL, Deckert M, Altman A. Views on Vav. Immunol Today 1997; 18: 221-5.
4. Fierro L, Lund PE, Parekh AB. Comparison of the activation of the Ca2+ release-activated Ca2+ current ICRAC to InsP3 in Jurkat T-lymphocytes, pulmonary artery endothelia and RBL-1 cells. Pflugers Arch 2000; 440: 580-7.
5. Neilson J, Stankunas K, Crabtree GR. Monitoring the duration of antigen-receptor occupancy by calcineurin/glycogen-synthase-kinase-3 control of NF-AT nuclear shuttling. Curr Opin Immunol 2001; 13: 346-50.
6. Feske S, Giltnane J, Dolmetsch R et al. Gene regulation mediated by calcium signals in T lymphocytes. Nature Immunol 2001; 2: 316-24.
7. Handschumacher RE, Harding MW, Rice J et al. Cyclophilin: A specific cytosolic binding protein for cyclosporin A. Science 1984; 226: 544-7.
8. Liu J, Farmer JD Jr., Lane WS et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66: 807-15.
9. Lyakh L, Ghosh P, Rice NR. Expression of NFAT-family proteins in normal human T cells. Mol Cell Biol 1997; 17: 2475-84.
10. Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: Regulation and function. Annu Rev Immunol 1997; 15: 707-47.
11. Matsuda S, Moriguchi T, Koyasu S et al. T lymphocyte activation signals for interleukin-2 production involve activation of MKK6-p38 and MKK7-SAPK/JNK signaling pathways sensitive to cyclosporin A. J Biol Chem 1998; 273: 12378-82.
12. Matsuda S, Shibasaki F, Takehana K et al. Two distinct action mechanisms of immunophilin-ligand complexes for the blockade of T-cell activation. EMBO Rep 2000; 1: 428-34.
13. Metcalfe S, Alexander D, Turner J. FK 506 and cyclosporin each block antigen-induced T cell receptor signalling that is dependent on CD4 co-receptor and operates in the absence of detectable cytoplasmic calcium fluxes. Transpl Int 1994; 7: S549-51.
14. Metcalfe S, Alexander D, Turner J. FK506 and cyclosporin A each inhibit antigen-specific signaling in the T cell line 171 in the absence of a calcium signal. Cell Immunol 1994; 158: 46-58.
15. Aramburu J, Yaffe MB, Lopez-Rodriguez C et al. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science 1999; 285: 2129-33.
16. Bierer BE, Mattila PS, Standaert RF et al. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci USA 1990; 87: 9231-5.
17. Halloran PF. Sirolimus and cyclosporin for renal transplantation. Lancet 2000; 356: 179-80.
18. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356: 194-202.
19. Ranger AM, Oukka M, Rengarajan J et al. Inhibitory function of two NFAT family members in lymphoid homeostasis and Th2 development. Immunity 1998; 9: 627-35.
20. Delling U, Tureckova J, Lim HW et al. A calcineurin-NFATc3-dependent pathway regulates skeletal muscle differentiation and slow myosin heavy-chain expression. Mol Cell Biol 2000; 20: 6600-11.
21. Ranger AM, Grusby MJ, Hodge MR et al. The transcription factor NF-ATc is essential for cardiac valve formation. Nature 1998; 392: 186-90.
22. de la Pompa JL, Timmerman LA, Takimoto H et al. Role of the NF-ATc transcription factor in morphogenesis of cardiac valves and septum. Nature 1998; 392: 182-6.
23. Northrop JP, Ho SN, Chen L et al. NF-AT components define a family of transcription factors targeted in T-cell activation. Nature 1994; 369: 497-502.
24. Nishio H, Matsui K, Tsuji H et al. Immunolocalization of calcineurin and FKBP12, the FK506-binding protein, in Hassall's corpuscles of human thymus and epidermis. Histochem Cell Biol 2000; 114: 9-14.
25. Santini MP, Talora C, Seki T et al. Cross talk among calcineurin, Sp1/Sp3, and NFAT in control of p21 (WAF1/CIP1) expression in keratinocyte differentiation. Proc Natl Acad Sci USA 2001; 98: 9575-80.
26. Al-Daraji WI, Grant KR, Ryan K et al. Localization of calcineurin/NFAT in human skin and psoriasis and inhibition of calcineurin/NFAT activation in human keratinocytes by cyclosporin A. J Invest Dermatol 2002; 118: 779-88.
27. Crabtree GR. Generic signals and specific outcomes: Signaling through Ca2+, calcineurin, and NF-AT. Cell 1999; 96: 611-4.
28. Tumlin JA. Expression and function of calcineurin in the mammalian nephron, physiological roles, receptor signaling, and ion transport. Am J Kidney Dis 1997; 30: 884-95.
29. Fisher GJ, Duell EA, Nickoloff BJ et al. Levels of cyclosporin in epidermis of treated psoriasis patients differentially inhibit growth of keratinocytes cultured in serum free versus serum containing media. J Invest Dermatol 1988; 91: 142-6.
30. Cooper KD, Baadsgaard O, Duell E et al. Langerhans cell sensitivity to in vitro versus in vivo loading with cyclosporine A. J Invest Dermatol 1992; 98: 259-61.
31. Javier AF, Bata-Csorgo Z, Ellis CN et al. Rapamycin (sirolimus) inhibits proliferating cell nuclear antigen expression and blocks cell cycle in the G1 phase in human keratinocyte stem cells. J Clin Invest 1997; 99: 2094-9.
32. Reynolds NJ, Voorhees JJ, Fisher GJ. Cyclosporin A inhibits 12-O-tetradecanoyl-phorbol-13-acetate-induced cutaneous inflammation in severe combined immunodeficient mice that lack functional lymphocytes. Br J Dermatol 1998; 139: 16-22.
33. Yamamoto S, Kato R. Hair growth-stimulating effects of cyclosporin A and FK506, potent immunosuppressants. J Dermatol Sci 1994; 7: S47-54.
34. Ali H, Ahamed J, Hernandez-Munain C et al. Chemokine production by G protein-coupled receptor activation in a human mast cell line: Roles of extracellular signal-regulated kinase and NFAT. J Immunol 2000; 165: 7215-23.
35. Furue M, Katz SI. The effect of cyclosporine on epidermal cells. I. Cyclosporine inhibits accessory cell functions of epidermal Langerhans cells in vitro. J Immunol 1988; 140: 4139-43.
36. Pigatto PD, Pigatto LB, Bigardi A et al. Factors secreted by untreated psoriatic monocytes enhance neutrophil functions. J Invest Dermatol 1990; 94: 372-6.
37. Prens EP, van Joost T, Hegmans JP et al. Effects of cyclosporine on cytokines and cytokine receptors in psoriasis. J Am Acad Dermatol 1995; 33: 947-53.
38. Ellis CN, Gorsulowsky DC, Hamilton TA et al. Cyclosporine improves psoriasis in a double-blind study. JAMA 1986; 256: 3110-6.
39. Jegasothy BV, Ackerman CD, Todo S et al. Tacrolimus (FK 506) - A new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol 1992; 128: 781-5.
40. The European FK 506 Multicentre Psoriasis Study Group. Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. The European FK 506 Multicentre Psoriasis Study Group. Arch Dermatol 1996; 132: 419-23.
41. Sowden JM, Berth-Jones J, Ross JS et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 1991; 338: 137-40.
42. Gupta AK, Ellis CN, Nickoloff BJ et al. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol 1990; 126: 339-50.
43. Berth-Jones J, Smith SG, Graham-Brown RA. Benign familial chronic pemphigus (Hailey-Hailey disease) responds to cyclosporin. Clin Exp Dermatol 1995; 20: 70-2.
44. Powles AV, Hardman CM, Porter WM et al. Renal function after 10 years' treatment with cyclosporin for psoriasis. Br J Dermatol 1998; 138: 443-9.
45. Meingassner JG, Grassberger M, Fahrngruber H et al. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: In vivo pharmacology. Br J Dermatol 1997; 137: 568-76.
46. Reitamo S, Spuls P, Sassolas B et al. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: A randomized controlled trial. Br J Dermatol 2001; 145: 438-45.
47. Kaplan MJ, Ellis CN, Bata-Csorgo Z et al. Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: Association of capillary leak syndrome with apoptosis of lesional lymphocytes. Arch Dermatol 1999; 135: 553-7.
48. Burns MK, Ellis CN, Eisen D et al. Intralesional cyclosporine for psoriasis. Relationship of dose, tissue levels, and efficacy. Arch Dermatol 1992; 128: 786-90.
49. Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol 2002; 46: 228-41.
50. Griffiths CE. Ascomycin: An advance in the management of atopic dermatitis. Br J Dermatol 2001; 144: 679-81.
51. Zonneveld IM, Rubins A, Jablonska S et al. Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol 1998; 134: 1101-2.
52. Allen DL, Sartorius CA, Sycuro LK et al. Different pathways regulate expression of the skeletal myosin heavy chain genes. J Biol Chem 2001; 10: 10.
53. Kelly DA, Young AR, McGregor JM et al. Sensitivity to sunburn is associated with susceptibility to ultraviolet radiation-induced suppression of cutaneous cell-mediated immunity. J Exp Med 2000; 191: 561-6.
54. Lopez-Rodriguez C, Aramburu J, Rakeman AS et al. NF-AT5: The NF-AT family of transcription factors expands in a new direction. Cold Spring Harb Symp Quant Biol 1999; 64: 517-26.